BenzingaOctober 21, 2026 at 7:58 AM NY6 Days Ago
Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13
Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $18 to $13.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
